Nasdaq grants GT Biopharma (NASDAQ: GTBP) 180-day minimum bid reprieve
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
GT Biopharma, Inc. received a notice from Nasdaq granting an additional 180-day period, until November 16, 2026, to regain compliance with the Nasdaq minimum bid price rule. To regain compliance, the company’s common stock must close at or above $1.00 per share for at least 10 consecutive business days.
Nasdaq granted the extension because GT Biopharma meets all other initial listing requirements for the Nasdaq Capital Market aside from the bid price rule. The company plans to monitor its share price and evaluate options, but it warns there is no assurance it will regain compliance or maintain its Nasdaq listing.
Positive
- None.
Negative
- Nasdaq minimum bid noncompliance and delisting risk: GT Biopharma remains out of compliance with Nasdaq’s $1.00 minimum bid price rule and only has until November 16, 2026 to cure the deficiency, with no assurance it will regain compliance or avoid potential delisting.
Insights
Nasdaq extension delays, but does not remove, delisting risk.
GT Biopharma has secured a further 180 days, until November 16, 2026, to lift its share price back above Nasdaq’s $1.00 minimum bid price requirement for at least 10 consecutive trading days. This avoids immediate delisting pressure.
The company currently satisfies other Nasdaq Capital Market listing criteria, which is why the extension was granted. However, the disclosure explicitly notes there is no assurance it will regain compliance, so the risk of losing the listing remains if the share price does not recover.
If GT Biopharma cannot achieve a sustained bid above $1.00 by November 16, 2026, Nasdaq may proceed toward delisting. That would likely affect trading liquidity and visibility, so future company actions aimed at meeting the bid requirement will be important context in later filings.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New compliance deadline: November 16, 2026
Minimum bid price requirement: $1.00 per share
Required compliance window: 10 consecutive business days
+3 more
6 metrics
New compliance deadline
November 16, 2026
End of additional 180-day Nasdaq bid price compliance period
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) threshold for common stock
Required compliance window
10 consecutive business days
Period during which bid must be at least $1.00
Initial deficiency notice date
November 20, 2025
Date Nasdaq first notified GT Biopharma of bid price deficiency
Initial compliance period end
May 19, 2026
End of first 180-day period before extension was granted
Common stock par value
$0.001 per share
Par value of GT Biopharma common stock
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Capital Market, emerging growth company, +1 more
5 terms
Minimum Bid Price Requirement financial
"which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price"
Nasdaq Capital Market market
"all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
emerging growth company regulatory
"or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Exhibit Number | | Description 104 | | Cover Page Interactive Data File, formatted in Inline XBRL"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did Nasdaq decide regarding GT Biopharma (GTBP) and its listing status?
Nasdaq granted GT Biopharma an additional 180-day compliance period, until November 16, 2026, to meet its minimum bid price rule. This postpones potential delisting but does not guarantee the company will restore compliance or maintain its Nasdaq Capital Market listing.
Why is GT Biopharma (GTBP) out of compliance with Nasdaq’s rules?
GT Biopharma is noncompliant with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Its common stock traded below $1.00 for 30 consecutive business days, triggering the deficiency notice originally received on November 20, 2025.
How long does GT Biopharma have to regain Nasdaq bid price compliance?
GT Biopharma now has until November 16, 2026, an additional 180 calendar days, to regain compliance. During this period, it must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days to satisfy Nasdaq’s requirement.
What conditions must GT Biopharma meet to satisfy Nasdaq’s minimum bid price rule?
To regain compliance, GT Biopharma’s common stock must close at or above $1.00 per share for at least 10 consecutive business days. Nasdaq may, at its discretion under Listing Rule 5810(c)(3)(H), extend this 10-day period before formally confirming compliance in writing.
Does GT Biopharma meet other Nasdaq Capital Market listing requirements?
Yes. Nasdaq granted the extension because GT Biopharma meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement specified in Listing Rule 5550(a)(2).
What risks does GT Biopharma (GTBP) highlight about its Nasdaq listing?
GT Biopharma cautions there is no assurance it will regain compliance with the minimum bid price requirement or remain in compliance with other Nasdaq rules. If it cannot cure the deficiency by November 16, 2026, the company faces a risk of potential delisting from Nasdaq.